Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Neoplasms | 114 | 2024 | 20982 | 4.100 |
Why?
|
Mastectomy, Segmental | 24 | 2022 | 955 | 2.400 |
Why?
|
Genetic Testing | 29 | 2024 | 3537 | 2.270 |
Why?
|
Genetic Counseling | 14 | 2024 | 628 | 1.800 |
Why?
|
Genetic Predisposition to Disease | 33 | 2024 | 17897 | 1.730 |
Why?
|
Penetrance | 3 | 2022 | 382 | 1.440 |
Why?
|
Carcinoma, Ductal, Breast | 14 | 2019 | 1084 | 1.360 |
Why?
|
Breast | 13 | 2021 | 1964 | 1.300 |
Why?
|
Mastectomy | 17 | 2021 | 1818 | 1.210 |
Why?
|
Mammography | 24 | 2024 | 2430 | 1.180 |
Why?
|
Mammary Glands, Human | 4 | 2019 | 202 | 1.160 |
Why?
|
Medical History Taking | 6 | 2014 | 773 | 1.150 |
Why?
|
Breast Neoplasms, Male | 5 | 2021 | 212 | 1.040 |
Why?
|
Natural Language Processing | 3 | 2019 | 1163 | 1.030 |
Why?
|
Tamoxifen | 6 | 2018 | 965 | 0.990 |
Why?
|
Germ-Line Mutation | 5 | 2022 | 1852 | 0.990 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 13 | 2019 | 926 | 0.920 |
Why?
|
Ovarian Neoplasms | 12 | 2018 | 4872 | 0.910 |
Why?
|
Anticarcinogenic Agents | 2 | 2018 | 249 | 0.900 |
Why?
|
Risk Assessment | 28 | 2024 | 24022 | 0.800 |
Why?
|
Receptors, Estrogen | 8 | 2024 | 2208 | 0.800 |
Why?
|
Carcinoma, Lobular | 9 | 2020 | 480 | 0.770 |
Why?
|
Stomach Neoplasms | 2 | 2022 | 1457 | 0.760 |
Why?
|
Mammaplasty | 6 | 2021 | 1232 | 0.710 |
Why?
|
Medical Oncology | 4 | 2017 | 2320 | 0.700 |
Why?
|
Genes, BRCA2 | 11 | 2021 | 591 | 0.690 |
Why?
|
Genes, BRCA1 | 11 | 2022 | 754 | 0.660 |
Why?
|
Practice Guidelines as Topic | 10 | 2019 | 7400 | 0.640 |
Why?
|
Antineoplastic Agents, Hormonal | 3 | 2013 | 1520 | 0.620 |
Why?
|
Gynecomastia | 1 | 2019 | 86 | 0.610 |
Why?
|
BRCA1 Protein | 5 | 2022 | 1149 | 0.600 |
Why?
|
Neoplasms | 10 | 2024 | 22142 | 0.580 |
Why?
|
Thyroid Neoplasms | 2 | 2021 | 2330 | 0.580 |
Why?
|
Decision Support Systems, Clinical | 3 | 2018 | 1172 | 0.560 |
Why?
|
Databases, Genetic | 2 | 2021 | 1741 | 0.560 |
Why?
|
Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2021 | 380 | 0.550 |
Why?
|
BRCA2 Protein | 4 | 2021 | 797 | 0.540 |
Why?
|
Ultrasonography, Mammary | 4 | 2016 | 239 | 0.510 |
Why?
|
Carcinoma in Situ | 3 | 2019 | 791 | 0.500 |
Why?
|
Germ Cells | 1 | 2019 | 632 | 0.490 |
Why?
|
Female | 117 | 2024 | 392552 | 0.490 |
Why?
|
Data Mining | 2 | 2018 | 552 | 0.490 |
Why?
|
Referral and Consultation | 4 | 2024 | 3608 | 0.480 |
Why?
|
Neoplasms, Second Primary | 2 | 2021 | 1052 | 0.480 |
Why?
|
Electronic Health Records | 4 | 2018 | 4822 | 0.470 |
Why?
|
Humans | 137 | 2024 | 761222 | 0.450 |
Why?
|
Neoplasm Recurrence, Local | 11 | 2021 | 9278 | 0.440 |
Why?
|
Risk Management | 4 | 2012 | 557 | 0.410 |
Why?
|
Receptors, Progesterone | 6 | 2024 | 1129 | 0.390 |
Why?
|
Genomics | 3 | 2017 | 5829 | 0.390 |
Why?
|
Genetic Association Studies | 1 | 2021 | 2731 | 0.380 |
Why?
|
Pharmacogenetics | 1 | 2015 | 675 | 0.370 |
Why?
|
Neoplasm Staging | 23 | 2020 | 11119 | 0.360 |
Why?
|
Chemoprevention | 1 | 2012 | 325 | 0.350 |
Why?
|
Sentinel Lymph Node Biopsy | 8 | 2020 | 732 | 0.350 |
Why?
|
Medical Informatics | 1 | 2017 | 733 | 0.350 |
Why?
|
Neoplastic Syndromes, Hereditary | 1 | 2012 | 246 | 0.330 |
Why?
|
Hyperplasia | 3 | 2019 | 1150 | 0.320 |
Why?
|
Aged | 53 | 2024 | 169292 | 0.320 |
Why?
|
Aged, 80 and over | 29 | 2020 | 58952 | 0.320 |
Why?
|
Lymphatic Metastasis | 10 | 2021 | 2913 | 0.310 |
Why?
|
Middle Aged | 63 | 2024 | 220858 | 0.310 |
Why?
|
Follow-Up Studies | 26 | 2024 | 39127 | 0.290 |
Why?
|
Neoplasm, Residual | 5 | 2021 | 1008 | 0.290 |
Why?
|
Adult | 62 | 2024 | 221120 | 0.290 |
Why?
|
Retrospective Studies | 44 | 2024 | 80675 | 0.270 |
Why?
|
Self Disclosure | 1 | 2007 | 249 | 0.260 |
Why?
|
Models, Statistical | 3 | 2020 | 5081 | 0.260 |
Why?
|
Age Factors | 16 | 2019 | 18384 | 0.260 |
Why?
|
Research Design | 2 | 2019 | 6180 | 0.260 |
Why?
|
Heterozygote | 2 | 2012 | 2778 | 0.250 |
Why?
|
Tumor Burden | 3 | 2021 | 1892 | 0.250 |
Why?
|
Mutation | 16 | 2022 | 30004 | 0.250 |
Why?
|
Precancerous Conditions | 3 | 2018 | 982 | 0.250 |
Why?
|
Adenocarcinoma | 1 | 2022 | 6341 | 0.240 |
Why?
|
Genetic Variation | 1 | 2020 | 6567 | 0.240 |
Why?
|
Carcinoma, Ductal | 2 | 2020 | 97 | 0.240 |
Why?
|
Mass Screening | 8 | 2011 | 5426 | 0.240 |
Why?
|
Quality Indicators, Health Care | 2 | 2014 | 1789 | 0.240 |
Why?
|
Prognosis | 22 | 2024 | 29688 | 0.240 |
Why?
|
Decision Support Techniques | 1 | 2014 | 2004 | 0.230 |
Why?
|
Nipples | 3 | 2021 | 229 | 0.220 |
Why?
|
Jews | 2 | 2018 | 356 | 0.220 |
Why?
|
Early Detection of Cancer | 4 | 2016 | 3198 | 0.220 |
Why?
|
Pancreatic Neoplasms | 1 | 2021 | 5366 | 0.210 |
Why?
|
Pedigree | 10 | 2018 | 4537 | 0.210 |
Why?
|
Pregnancy Complications, Neoplastic | 1 | 2005 | 258 | 0.210 |
Why?
|
Massachusetts | 8 | 2021 | 8837 | 0.200 |
Why?
|
Attitude to Health | 3 | 2008 | 2026 | 0.200 |
Why?
|
Colonic Neoplasms | 1 | 2014 | 2527 | 0.200 |
Why?
|
Data Collection | 2 | 2009 | 3320 | 0.190 |
Why?
|
Women's Health | 1 | 2011 | 2070 | 0.190 |
Why?
|
SEER Program | 3 | 2021 | 1453 | 0.190 |
Why?
|
Mastectomy, Subcutaneous | 1 | 2021 | 56 | 0.190 |
Why?
|
Heredity | 3 | 2018 | 148 | 0.170 |
Why?
|
Receptor, erbB-2 | 5 | 2024 | 2553 | 0.170 |
Why?
|
Risk Factors | 24 | 2024 | 74241 | 0.170 |
Why?
|
Cohort Studies | 9 | 2021 | 41496 | 0.170 |
Why?
|
Software | 4 | 2018 | 4431 | 0.160 |
Why?
|
Radio Frequency Identification Device | 1 | 2019 | 24 | 0.160 |
Why?
|
Magnetic Resonance Imaging | 8 | 2019 | 36415 | 0.160 |
Why?
|
Biopsy | 6 | 2019 | 6781 | 0.160 |
Why?
|
Needs Assessment | 2 | 2017 | 1141 | 0.160 |
Why?
|
Chemotherapy, Adjuvant | 4 | 2021 | 3512 | 0.160 |
Why?
|
Healthcare Disparities | 2 | 2024 | 3354 | 0.160 |
Why?
|
Reproducibility of Results | 7 | 2019 | 20118 | 0.150 |
Why?
|
Abdominal Fat | 1 | 2020 | 221 | 0.150 |
Why?
|
Predictive Value of Tests | 12 | 2019 | 15308 | 0.150 |
Why?
|
Reoperation | 5 | 2021 | 4303 | 0.150 |
Why?
|
Hemangiosarcoma | 1 | 2020 | 215 | 0.150 |
Why?
|
Estrogen Replacement Therapy | 2 | 2009 | 1208 | 0.150 |
Why?
|
X-Ray Microtomography | 1 | 2020 | 450 | 0.140 |
Why?
|
Carcinoma | 3 | 2003 | 2330 | 0.140 |
Why?
|
Databases, Factual | 3 | 2018 | 7965 | 0.140 |
Why?
|
Hypertrophy | 1 | 2019 | 558 | 0.140 |
Why?
|
Legislation, Medical | 1 | 2016 | 98 | 0.130 |
Why?
|
Neoplasm Invasiveness | 8 | 2018 | 3590 | 0.130 |
Why?
|
Guideline Adherence | 3 | 2018 | 2220 | 0.120 |
Why?
|
Lymph Node Excision | 4 | 2020 | 1270 | 0.120 |
Why?
|
Survival Rate | 7 | 2021 | 12728 | 0.120 |
Why?
|
Treatment Refusal | 1 | 2018 | 430 | 0.120 |
Why?
|
Neoplasms, Radiation-Induced | 2 | 2009 | 549 | 0.120 |
Why?
|
Kaplan-Meier Estimate | 2 | 2017 | 6486 | 0.120 |
Why?
|
Health Status | 1 | 2008 | 4077 | 0.120 |
Why?
|
Salvage Therapy | 1 | 2021 | 1264 | 0.120 |
Why?
|
Workflow | 1 | 2019 | 850 | 0.120 |
Why?
|
Analgesics, Opioid | 2 | 2022 | 3805 | 0.120 |
Why?
|
United States | 9 | 2021 | 72341 | 0.110 |
Why?
|
Registries | 6 | 2020 | 8246 | 0.110 |
Why?
|
Young Adult | 15 | 2021 | 59222 | 0.110 |
Why?
|
Incidental Findings | 1 | 2018 | 698 | 0.110 |
Why?
|
Radiotherapy, Conformal | 2 | 2006 | 548 | 0.100 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 1 | 2020 | 1221 | 0.100 |
Why?
|
Neoadjuvant Therapy | 3 | 2020 | 2827 | 0.100 |
Why?
|
American Cancer Society | 1 | 2012 | 69 | 0.100 |
Why?
|
Survivors | 1 | 2003 | 2369 | 0.100 |
Why?
|
Biopsy, Fine-Needle | 2 | 2016 | 1118 | 0.100 |
Why?
|
Costs and Cost Analysis | 3 | 2015 | 1664 | 0.100 |
Why?
|
2-Aminopurine | 1 | 2011 | 11 | 0.100 |
Why?
|
Congresses as Topic | 1 | 2017 | 803 | 0.100 |
Why?
|
Neoplasm Metastasis | 3 | 2016 | 4909 | 0.100 |
Why?
|
Gene Expression Profiling | 2 | 2018 | 9417 | 0.100 |
Why?
|
Combined Modality Therapy | 6 | 2015 | 8519 | 0.100 |
Why?
|
Diffusion of Innovation | 1 | 2016 | 730 | 0.100 |
Why?
|
Watchful Waiting | 1 | 2015 | 489 | 0.090 |
Why?
|
Time Factors | 8 | 2021 | 39957 | 0.090 |
Why?
|
Axilla | 4 | 2020 | 624 | 0.090 |
Why?
|
Disease Management | 2 | 2019 | 2507 | 0.090 |
Why?
|
Hodgkin Disease | 2 | 2009 | 1379 | 0.090 |
Why?
|
Radiographic Image Enhancement | 1 | 2015 | 877 | 0.090 |
Why?
|
Androstadienes | 1 | 2012 | 348 | 0.090 |
Why?
|
Phenotype | 4 | 2018 | 16575 | 0.090 |
Why?
|
Algorithms | 4 | 2019 | 14025 | 0.090 |
Why?
|
JNK Mitogen-Activated Protein Kinases | 1 | 2011 | 438 | 0.090 |
Why?
|
Pathology, Clinical | 1 | 2013 | 376 | 0.080 |
Why?
|
Survival Analysis | 7 | 2017 | 10088 | 0.080 |
Why?
|
Radiotherapy | 2 | 2008 | 1500 | 0.080 |
Why?
|
Sensitivity and Specificity | 5 | 2015 | 14675 | 0.080 |
Why?
|
Incidence | 6 | 2019 | 21366 | 0.080 |
Why?
|
Pain, Postoperative | 1 | 2019 | 1741 | 0.080 |
Why?
|
Purines | 1 | 2011 | 609 | 0.080 |
Why?
|
Calcinosis | 2 | 2008 | 1477 | 0.080 |
Why?
|
Risk | 2 | 2019 | 9616 | 0.080 |
Why?
|
Terminology as Topic | 1 | 2015 | 1528 | 0.070 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2013 | 1784 | 0.070 |
Why?
|
Prevalence | 4 | 2018 | 15721 | 0.070 |
Why?
|
Adolescent | 6 | 2019 | 88300 | 0.070 |
Why?
|
Computational Biology | 1 | 2019 | 3499 | 0.070 |
Why?
|
Treatment Outcome | 9 | 2019 | 64681 | 0.070 |
Why?
|
Microcomputers | 1 | 2007 | 140 | 0.070 |
Why?
|
Proportional Hazards Models | 1 | 2021 | 12474 | 0.070 |
Why?
|
Health Care Surveys | 1 | 2014 | 2425 | 0.070 |
Why?
|
Surgical Equipment | 1 | 2006 | 57 | 0.070 |
Why?
|
Imaging, Three-Dimensional | 1 | 2020 | 4052 | 0.070 |
Why?
|
Medication Adherence | 1 | 2018 | 2175 | 0.070 |
Why?
|
Prenatal Care | 1 | 2014 | 1141 | 0.070 |
Why?
|
Lymphedema | 1 | 2012 | 523 | 0.060 |
Why?
|
Program Evaluation | 1 | 2014 | 2489 | 0.060 |
Why?
|
Societies, Medical | 1 | 2017 | 3923 | 0.060 |
Why?
|
Diagnostic Imaging | 1 | 2019 | 3534 | 0.060 |
Why?
|
Reperfusion Injury | 1 | 2011 | 1026 | 0.060 |
Why?
|
Premenopause | 2 | 2021 | 1039 | 0.060 |
Why?
|
Brachytherapy | 1 | 2012 | 1223 | 0.060 |
Why?
|
Mathematics | 2 | 2003 | 702 | 0.060 |
Why?
|
Life Expectancy | 2 | 2008 | 1242 | 0.060 |
Why?
|
Patient Education as Topic | 2 | 2016 | 2317 | 0.060 |
Why?
|
Antineoplastic Agents | 3 | 2021 | 13632 | 0.050 |
Why?
|
Evidence-Based Medicine | 1 | 2015 | 3691 | 0.050 |
Why?
|
Dyspareunia | 1 | 2003 | 48 | 0.050 |
Why?
|
Age of Onset | 2 | 2016 | 3307 | 0.050 |
Why?
|
Patient Selection | 2 | 2012 | 4246 | 0.050 |
Why?
|
Vaginal Diseases | 1 | 2003 | 103 | 0.050 |
Why?
|
Postmenopause | 3 | 2021 | 2514 | 0.050 |
Why?
|
Male | 11 | 2021 | 360703 | 0.050 |
Why?
|
Guidelines as Topic | 1 | 2008 | 1385 | 0.050 |
Why?
|
Cross-Sectional Studies | 2 | 2018 | 26072 | 0.050 |
Why?
|
Communication | 1 | 2016 | 3872 | 0.050 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 2004 | 410 | 0.050 |
Why?
|
Immunohistochemistry | 3 | 2024 | 11067 | 0.050 |
Why?
|
Decision Making, Computer-Assisted | 1 | 2002 | 146 | 0.050 |
Why?
|
Phylogeny | 1 | 2009 | 2809 | 0.050 |
Why?
|
Internet | 1 | 2013 | 3096 | 0.050 |
Why?
|
Body Mass Index | 4 | 2021 | 12952 | 0.050 |
Why?
|
Odds Ratio | 1 | 2013 | 9652 | 0.050 |
Why?
|
Hemangioma | 1 | 2005 | 727 | 0.040 |
Why?
|
Pilot Projects | 1 | 2014 | 8642 | 0.040 |
Why?
|
Hot Flashes | 1 | 2003 | 330 | 0.040 |
Why?
|
Osteoporosis, Postmenopausal | 1 | 2003 | 396 | 0.040 |
Why?
|
Data Interpretation, Statistical | 1 | 2009 | 2691 | 0.040 |
Why?
|
Cost-Benefit Analysis | 1 | 2012 | 5493 | 0.040 |
Why?
|
Health Care Costs | 1 | 2012 | 3239 | 0.040 |
Why?
|
Diagnosis, Differential | 3 | 2018 | 12976 | 0.040 |
Why?
|
Intraoperative Period | 1 | 2020 | 510 | 0.040 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2017 | 11733 | 0.040 |
Why?
|
Tissue Expansion Devices | 1 | 2019 | 156 | 0.040 |
Why?
|
Disease-Free Survival | 2 | 2021 | 6819 | 0.040 |
Why?
|
Uterine Neoplasms | 1 | 2007 | 1420 | 0.040 |
Why?
|
Peptide Hydrolases | 1 | 2021 | 616 | 0.040 |
Why?
|
Primary Health Care | 3 | 2016 | 4679 | 0.040 |
Why?
|
Mood Disorders | 1 | 2003 | 1124 | 0.030 |
Why?
|
ROC Curve | 1 | 2024 | 3584 | 0.030 |
Why?
|
Gestational Age | 1 | 2005 | 3580 | 0.030 |
Why?
|
Prospective Studies | 6 | 2021 | 54437 | 0.030 |
Why?
|
Physician-Patient Relations | 1 | 2009 | 3253 | 0.030 |
Why?
|
Breast Implants | 1 | 2019 | 407 | 0.030 |
Why?
|
Preoperative Care | 2 | 2019 | 2241 | 0.030 |
Why?
|
Specimen Handling | 1 | 2020 | 702 | 0.030 |
Why?
|
Perimenopause | 1 | 2016 | 142 | 0.030 |
Why?
|
Age Distribution | 3 | 2005 | 2871 | 0.030 |
Why?
|
Pregnancy | 3 | 2019 | 29893 | 0.030 |
Why?
|
Decision Trees | 1 | 2015 | 505 | 0.030 |
Why?
|
Biopsy, Needle | 1 | 2019 | 1624 | 0.030 |
Why?
|
Coloring Agents | 1 | 2016 | 561 | 0.030 |
Why?
|
Hemoglobinopathies | 1 | 2014 | 99 | 0.030 |
Why?
|
Probability | 3 | 2004 | 2478 | 0.030 |
Why?
|
Feasibility Studies | 1 | 2024 | 5250 | 0.030 |
Why?
|
Patient Satisfaction | 2 | 2021 | 3453 | 0.030 |
Why?
|
Skin | 1 | 2006 | 4473 | 0.030 |
Why?
|
Multivariate Analysis | 2 | 2019 | 12052 | 0.030 |
Why?
|
Immunoenzyme Techniques | 1 | 2015 | 1703 | 0.030 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2020 | 2024 | 0.020 |
Why?
|
Models, Economic | 1 | 2015 | 714 | 0.020 |
Why?
|
Haplorhini | 1 | 2011 | 523 | 0.020 |
Why?
|
Inhibitory Concentration 50 | 1 | 2011 | 464 | 0.020 |
Why?
|
Body Composition | 1 | 2020 | 2427 | 0.020 |
Why?
|
Preventive Medicine | 1 | 2012 | 245 | 0.020 |
Why?
|
Models, Theoretical | 1 | 2002 | 3571 | 0.020 |
Why?
|
Cost Savings | 1 | 2015 | 911 | 0.020 |
Why?
|
Chi-Square Distribution | 2 | 2006 | 3418 | 0.020 |
Why?
|
In Situ Hybridization | 1 | 2013 | 1900 | 0.020 |
Why?
|
Molecular Imaging | 1 | 2016 | 818 | 0.020 |
Why?
|
Arm | 1 | 2012 | 589 | 0.020 |
Why?
|
Catalytic Domain | 1 | 2011 | 702 | 0.020 |
Why?
|
Regression Analysis | 1 | 2019 | 6345 | 0.020 |
Why?
|
Lymph Nodes | 1 | 2020 | 3461 | 0.020 |
Why?
|
Computer Simulation | 1 | 2002 | 6224 | 0.020 |
Why?
|
Case-Control Studies | 2 | 2020 | 22174 | 0.020 |
Why?
|
Postoperative Period | 1 | 2012 | 1818 | 0.020 |
Why?
|
Molecular Structure | 1 | 2011 | 1875 | 0.020 |
Why?
|
Information Dissemination | 1 | 2016 | 1129 | 0.020 |
Why?
|
Colorectal Neoplasms | 1 | 2007 | 6919 | 0.020 |
Why?
|
Models, Biological | 1 | 2003 | 9458 | 0.020 |
Why?
|
Dogs | 1 | 2011 | 3832 | 0.020 |
Why?
|
User-Computer Interface | 1 | 2013 | 1393 | 0.020 |
Why?
|
Health Services Accessibility | 1 | 2024 | 5426 | 0.020 |
Why?
|
Telangiectasis | 1 | 2006 | 78 | 0.020 |
Why?
|
Genes, p53 | 1 | 2009 | 713 | 0.020 |
Why?
|
Structure-Activity Relationship | 1 | 2011 | 3057 | 0.020 |
Why?
|
Enzyme Activation | 1 | 2011 | 3577 | 0.020 |
Why?
|
Length of Stay | 1 | 2019 | 6417 | 0.020 |
Why?
|
Decision Making | 1 | 2019 | 3931 | 0.020 |
Why?
|
Recurrence | 1 | 2017 | 8457 | 0.020 |
Why?
|
Esthetics | 1 | 2006 | 327 | 0.010 |
Why?
|
Cystic Fibrosis | 1 | 2014 | 1283 | 0.010 |
Why?
|
Electrons | 1 | 2006 | 265 | 0.010 |
Why?
|
Italy | 1 | 2006 | 844 | 0.010 |
Why?
|
False Positive Reactions | 1 | 2006 | 958 | 0.010 |
Why?
|
Intraoperative Care | 1 | 2007 | 767 | 0.010 |
Why?
|
PTEN Phosphohydrolase | 1 | 2009 | 1111 | 0.010 |
Why?
|
Cultural Characteristics | 1 | 2004 | 250 | 0.010 |
Why?
|
Interdisciplinary Communication | 1 | 2008 | 931 | 0.010 |
Why?
|
Photons | 1 | 2006 | 589 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2005 | 20588 | 0.010 |
Why?
|
Models, Molecular | 1 | 2011 | 5406 | 0.010 |
Why?
|
Enzyme Inhibitors | 1 | 2011 | 3702 | 0.010 |
Why?
|
Aromatase Inhibitors | 1 | 2005 | 513 | 0.010 |
Why?
|
Statistics, Nonparametric | 1 | 2006 | 2854 | 0.010 |
Why?
|
Quality Improvement | 1 | 2016 | 3808 | 0.010 |
Why?
|
Patient Acceptance of Health Care | 2 | 2004 | 3200 | 0.010 |
Why?
|
Diagnostic Errors | 1 | 2007 | 1265 | 0.010 |
Why?
|
Primary Prevention | 1 | 2007 | 1185 | 0.010 |
Why?
|
Radiotherapy Dosage | 1 | 2006 | 2897 | 0.010 |
Why?
|
Radiography | 1 | 2009 | 6974 | 0.010 |
Why?
|
Perioperative Care | 1 | 2005 | 1037 | 0.010 |
Why?
|
Educational Status | 1 | 2004 | 2510 | 0.010 |
Why?
|
Patient Care Team | 1 | 2008 | 2515 | 0.010 |
Why?
|
Stress, Psychological | 1 | 2012 | 4487 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2012 | 8531 | 0.010 |
Why?
|
Cell Division | 1 | 2003 | 4451 | 0.010 |
Why?
|
Rats | 1 | 2011 | 23705 | 0.010 |
Why?
|
Comorbidity | 1 | 2008 | 10516 | 0.010 |
Why?
|
Patient Compliance | 1 | 2003 | 2688 | 0.010 |
Why?
|
Mortality | 1 | 2003 | 2896 | 0.010 |
Why?
|
Socioeconomic Factors | 1 | 2004 | 7804 | 0.010 |
Why?
|
Child | 2 | 2009 | 80154 | 0.010 |
Why?
|
Ultrasonography | 1 | 2003 | 5969 | 0.010 |
Why?
|
Child, Preschool | 1 | 2008 | 42225 | 0.000 |
Why?
|
Animals | 1 | 2011 | 168089 | 0.000 |
Why?
|